» Articles » PMID: 1761814

Circulating Soluble Interleukin 2 Receptor Concentration is Increased in Both Immunogenic and Nonimmunogenic Hyperthyroidism

Overview
Publisher Springer
Specialty Endocrinology
Date 1991 Oct 1
PMID 1761814
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

High serum concentration of soluble interleukin-2 receptor (sIL-2R) is considered a reliable marker of T lymphocyte activation. It has been recently reported that sIL-2R levels are increased in untreated Graves' disease. This finding has been interpreted as the consequence of an active autoimmune state, but the relevance of the thyroid function per se was not investigated. In the present study we assayed sIL-2R by ELISA in 20 normal subjects and in a series of patients with immunogenic (Graves' disease, GD) or nonimmunogenic (toxic adenoma, TA) hyperthyroidism. Significant increased concentrations of sIL-2R were found in 46 patients with untreated hyperthyroid GD (mean +/- SD: 1,683 +/- 1016 U/ml, vs 461 +/- 186 U/ml in normal controls, p less than 0.0001) and in 21 with untreated TA (1,111 +/- 617 U/ml, p less than 0.0001 vs normals). Restoration of the euthyroid state by antithyroid drugs or 131I administration was associated with a normalization of sIL-2R (516 +/- 174 U/ml in 38 patients with GD and 365 +/- 90 U/ml in 12 with TA; p = NS vs normals and p less than 0.001 vs the untreated state for both groups). A highly significant positive correlation between serum sIL-2R and free triiodothyronine (FT3) (r = 0.724, p less than 0.0001) or free thyroxine (FT4) (r = 0.698, p less than 0.0001) concentrations was found in combined sera obtained from all untreated and treated patients, irrespectively of the autoimmune or nonautoimmune nature of the underlying hyperthyroid disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

The Predicting Role of Serum TSGF and sIL-2R for the Lymph Node Metastasis of Papillary Thyroid Carcinoma.

Xu X, Wang W, Sun T, Tian B, Du L, Jing J Dis Markers. 2022; 2022:3730679.

PMID: 36092957 PMC: 9463009. DOI: 10.1155/2022/3730679.


Clinical Application Value of High-Frequency Ultrasound Combined with Detection of Serum High Mobility Group Box 1, Soluble IL-2 Receptor, and Thyroglobulin Antibody in Diagnosing Thyroid Cancer.

Li N, Zhang J, Meng X, Yao W J Healthc Eng. 2022; 2022:7851436.

PMID: 35392142 PMC: 8983246. DOI: 10.1155/2022/7851436.


The Impact of Iodine Exposure in Excess on Hormonal Aspects and Hemato-Biochemical Profile in Rats.

Ismail H Biol Trace Elem Res. 2021; 200(2):706-719.

PMID: 33783684 DOI: 10.1007/s12011-021-02681-7.


Biological significance of soluble IL-2 receptor.

Caruso C, Candore G, Cigna D, Colucci A, Modica M Mediators Inflamm. 1993; 2(1):3-21.

PMID: 18475497 PMC: 2365387. DOI: 10.1155/S0962935193000018.


Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.

Smallridge R, Tsokos G, Burman K, Porter L, Cranston T, Sfikakis P Clin Diagn Lab Immunol. 1997; 4(5):583-6.

PMID: 9302209 PMC: 170601. DOI: 10.1128/cdli.4.5.583-586.1997.


References
1.
Rubin L, Nelson D . The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990; 113(8):619-27. DOI: 10.7326/0003-4819-113-8-619. View

2.
Sztein M, Serrate S, Goldstein A . Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci U S A. 1986; 83(16):6107-11. PMC: 386448. DOI: 10.1073/pnas.83.16.6107. View

3.
Marcocci C, Chiovato L, Mariotti S, Pinchera A . Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves' disease. J Endocrinol Invest. 1982; 5(1):13-9. DOI: 10.1007/BF03350476. View

4.
Leichtling K, Serrate S, Sztein M . Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol. 1990; 12(1):19-29. DOI: 10.1016/0192-0561(90)90064-t. View

5.
Fabris N, Mocchegiani E, Mariotti S, Pacini F, Pinchera A . Thyroid-thymus interactions during development and aging. Horm Res. 1989; 31(1-2):85-9. DOI: 10.1159/000181093. View